PFS

Provident Financial Services, Inc.
$22.54
+0.01 (+0.04%)
Mkt Cap 2.93B
Volume 538,633
52W Range 17.7-25.49
Sector Financial Services
Beta 0.82
EPS (TTM) 2.40 USD
P/E Ratio 9.36
Revenue (TTM) 1.38B USD
Rev Growth (5Y) +26.0%
EPS Growth (5Y) +9.9%
AlphaVal · Fair Value
What we estimate one share is worth
$33.18
Undervalued moderate signal
32.3% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
B
Banks, Insurers & Asset Managers
70.7 / 100 composite
A bank, insurer or asset manager — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 1.38B 1.14B 695.65M 553.97M 489.15M 435.74M 435.26M 418.50M 379.54M 357.71M 347.00M 320.53M
Net Income 291.16M 115.53M 128.40M 175.65M 167.92M 96.95M 112.63M 118.39M 93.95M 87.80M 83.72M 73.63M
EPS 2.23 1.05 1.72 2.35 2.20 1.39 1.74 1.82 1.46 1.38 1.33 1.22
Free Cash Flow 430.73M 425.07M 165.91M 190.90M 143.01M 90.48M 132.04M 152.56M 113.99M 122.31M 108.96M 85.23M
FCF / Share 3.30 3.88 2.22 2.56 1.87 1.30 2.04 2.35 1.77 1.92 1.73 1.41
Operating CF 442.26M 426.38M 173.40M 200.31M 156.81M 103.30M 136.93M 155.72M 117.22M 127.31M 114.87M 101.67M
Total Assets 24.98B 24.05B 14.21B 13.78B 13.78B 12.92B 9.81B 9.73B 9.85B 9.50B 8.91B 8.52B
Total Debt 2.52B 2.42B 1.53B 1.35B 637.06M 1.20B 1.13B 1.44B 1.74B 1.61B 1.71B 1.51B
Cash & Equiv 211.48M 205.91M 180.25M 186.44M 712.46M 532.35M 186.75M 142.66M 190.83M 144.30M 102.23M 103.76M
Book Value 2.83B 2.60B 1.69B 1.60B 1.70B 1.62B 1.41B 1.36B 1.30B 1.25B 1.20B 1.14B
Return on Equity 0.10 0.04 0.08 0.11 0.10 0.06 0.08 0.09 0.07 0.07 0.07 0.06
PFS News
Provident Financial (PFS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Oct 21, 2026 07:06 AM · zacks.com
IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
Oct 19, 2026 02:00 AM · prnewswire.com
/C O R R E C T I O N - AbbVie/
Oct 18, 2026 06:00 PM · gurufocus.com
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
Oct 18, 2026 03:00 PM · gurufocus.com
Bristol Myers Squibb (BMY) Gains on Positive Phase 3 Results for RYZ101 and Admilparant
Oct 12, 2026 07:14 AM · gurufocus.com
Provident Financial Services (NYSE:PFS) & F.N.B. (NYSE:FNB) Financial Review
Oct 11, 2026 09:44 PM · defenseworld.net
Provident Financial Services (NYSE:PFS) & Capital Bancorp (NASDAQ:CBNK) Financial Comparison
Oct 10, 2026 10:59 PM · defenseworld.net
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Oct 06, 2026 05:00 AM · gurufocus.com
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
Oct 05, 2026 11:00 AM · gurufocus.com
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
Oct 05, 2026 11:00 AM · gurufocus.com